Del Fante Claudia, Vertui Valentina, Klersy Catherine, Mortellaro Cristina, Briganti Domenica Federica, Morlacchi Letizia Corinna, Russo Marianna, Perotti Cesare, Meloni Federica
Immunohaematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Cardiothoracic and Vascular Department, Unit of Respiratory Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Transfusion. 2025 Aug;65(8):1490-1501. doi: 10.1111/trf.18318. Epub 2025 Jul 14.
Several studies show that extracorporeal photopheresis (ECP) might benefit chronic lung allograft dysfunction (CLAD). A standard ECP cycle consists of two consecutive procedures regardless of the technique employed.
Evaluation of ECP cycle (from two to one procedure) modification due to pandemic restrictions in 25 patients with CLAD under chronic treatment by off-line ECP in the 6 months preceding cycle modification (one procedure processing 1.5 patients blood volumes [1.5 ECP]). Assessment of any significant change in lung function decline and the relationship with product characteristics compared to pre-ECP cycle modification.
ECP patients (23 obstructive and two mixed) were enrolled in 2020 during the COVID pandemic. Two hundred and thirty five ECP procedures followed the standard protocol and 121 the 1.5 ECP. There was little or no variation in lung function during the study period. The mean number of mononuclear cells (MNC) per kg administered over time was higher in the 1.5 ECP than in the standard ECP protocol (p = .014). No association was found between respiratory function and MNC infused. Persistent Forced Expiratory Volume in 1 s decline >10% was observed in two patients over the 6 months preceding 1.5 ECP (due to CLAD progression) and in three patients after 1.5 ECP initiation (one for CLAD progression, two for bronchial colonization).
Our study shows that respiratory function is maintained over time and is comparable between both ECP strategies in responders. The shift from two to one procedure per cycle may be reasonable in CLAD patients treated by off-line ECP.
多项研究表明,体外光化学疗法(ECP)可能对慢性肺移植功能障碍(CLAD)有益。无论采用何种技术,标准的ECP周期均由两个连续的程序组成。
评估在周期调整前6个月接受离线ECP慢性治疗的25例CLAD患者因大流行限制而对ECP周期(从两个程序改为一个程序)的调整情况(一个程序处理1.5倍患者血容量[1.5 ECP])。评估肺功能下降的任何显著变化以及与ECP周期调整前相比与产品特性的关系。
ECP患者(23例阻塞性和2例混合型)于2020年新冠疫情期间入组。235次ECP程序遵循标准方案,121次采用1.5 ECP。研究期间肺功能几乎没有变化。随着时间的推移,1.5 ECP每千克给予的单核细胞(MNC)平均数高于标准ECP方案(p = 0.014)。未发现呼吸功能与输注MNC之间存在关联。在1.5 ECP前6个月有两名患者出现持续1秒用力呼气量下降>10%(由于CLAD进展),在开始1.5 ECP后有三名患者出现(一名因CLAD进展,两名因支气管定植)。
我们的研究表明,随着时间的推移呼吸功能得以维持,且两种ECP策略在有反应者中具有可比性。对于接受离线ECP治疗的CLAD患者,每个周期从两个程序改为一个程序可能是合理的。